US Patent

US10294215 — Therapeutically active compounds and their methods of use

Method of Use · Assigned to Agios Pharmaceuticals Inc · Expires 2033-01-07 · 7y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects compounds useful for treating cancer and methods of using those compounds to treat cancer.

USPTO Abstract

Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

Drugs covered by this patent

enasidenib-mesylate (ENASIDENIB MESYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2087`	—	enasidenib-mesylate
`U-2087`	—	enasidenib-mesylate

Patent Metadata

Patent number: US10294215
Jurisdiction: US
Classification: Method of Use
Expires: 2033-01-07
Drug substance claim: No
Drug product claim: Yes
Assignee: Agios Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.